CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
4 research outputs found
A Targeted RNAi Screen of the Breast Cancer Genome Identifies KIF14
Author
Crystal Cornelius
Gail Fasciani
+6 more
Jerry W. Shay
Kimberly Batten
Lawrence Lum
Shay
Stina Mui Singel
Woodring E. Wright
Publication venue
'American Association for Cancer Research (AACR)'
Publication date
Field of study
No full text
Crossref
LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).
Author
Antoinette R. Tan
Cristina Saura
+8 more
Mafalda Oliveira
Rafael Villanueva
Rebecca Alexandra Dent
Seock-Ah Im
Steven J. Isakoff
Stina Mui Singel
Sung-Bae Kim
Vicente Valero
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC).
Author
Antonio Gonzalez-Martin
Cristina Saura
+15 more
Eva Ciruelos
Isabel Calvo
Jay C. Andersen
Jose Baselga
Julie Gottlieb Fisher
Lorena De La Pena
Mafalda Oliveira
Marta Llobet-Canela
Miquel Gil
Premal H. Patel
Shidong Jia
Sreenivasu Yalamanchili
Steven J. Isakoff
Stina Mui Singel
YounJeong Choi
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer.
Author
Amy V. Kapp
Cristina Saura
+16 more
Daniel J. Maslyar
Debra A. Patt
EVA Ciruelos
Isabel Calvo
Jay C. Andersen
Jose Baselga
Jose Passos-Coelho
Julie Gottlieb Fisher
Lorena de La Pena
Mafalda Oliveira
Miguel J. Gil Gil
Serafin Morales Murillo
Steven Gendreau
Steven J. Isakoff
Stina Mui Singel
Wai Y. Chan
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref